Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Now in its 19th year, the Scrip Awards brings together over 400 industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 14 categories, covering the whole spectrum of advancements, from Best New Drug, Community Partnership of the Year, Best Contract Research Organisation as well as a new category for 2023, Best Oncology R&D Advance.
All entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity. This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Thursday 16 November at our brand-new venue, The Oceandiva on the River Thames!
It is with great sadness that we remember Scrip Awards judge, Bill Bishop. In Memoriam
The Best New Drug Award recognises excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D. In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area. All recently launched new active substances, including small molecules, biologicals or vaccines, are eligible to enter so long as they were first licensed in any market between 1 June 2022 - 30 June 2023. Generic and biosimilar products are not eligible for this Award.
To enter this category, please answer the following:
Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.
This Award seeks to recognise success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product. The product involved need not yet be approved, but the judges will be looking for innovation, clear proof of benefit and potential commercial reward. To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 June 2022 - 30 June 2023.
To enter this category, please answer the following:
Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies over the qualifying 12 months.
To enter this category, please answer the following:
The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between 1 June 2022 - 30 June 2023. For example, this could be moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.
This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organisation.
To enter this category, please answer the following:
The judges will be looking for effective partnership activity, which took place between 1 June 2022 - 30 June 2023, to the benefit of humankind. For example, these types of partnerships could include patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.
Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.
To enter this category, please answer the following:
This year’s winner will be the executive who has exhibited exemplary leadership throughout the year from 1 June 2022 - 30 June 2023. This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities. To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing. Please note, it does not include more involved partnerships between companies to explore particular therapeutic strategies (see Criteria for the Best Partnership Alliance).
To enter this category, please answer the following:
In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between 1 June 2022 - 30 June 2023.
Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.
To enter this category, please answer the following:
This Award will go to a team that is truly much more than the sum of its parts. The Judges will be looking for strong performance across a number of criteria, such as achievement of short- and long-term goals, and good communication of a shared vision.
The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
To enter this category, please answer the following:
This Award is for the companies who provide the full range of clinical research services and they will be judged on the quality of these services and relationships the firms have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal. To qualify, candidates must draw on their achievements in the year between 1 June 2022 - 30 June 2023.
The Awards for the Best Contract Research Organisation acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
To enter this category, please answer the following:
This Award is for those companies who provide niche services to their clients will be judged on the quality of these services and relationships they have built with their clients. To qualify, candidates must draw on their achievements in the year between 1 June 2022 - 30 June 2023.
Scrip’s Best Partnership Alliance Award recognises the importance of pharmaceutical and/or biotech companies working together to develop new medicines from the earliest stages. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in exploring novel therapeutic strategies and developing new drugs.
To enter this category, please answer the following:
The judges will be focusing on deals that require strong strategic input from both partners, involving R&D, business development or joint marketing/promotion. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure. Partnerships must have been announced, or have achieved a significant milestone, between 1 June 2022 - 30 June 2023, and entrants should be able to show some benefits arising from the deal.
Please note, this Award does not cover the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing (see Criteria for Licensing Deal of the Year).
This category will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judging panel believes has the potential to be transformative in the discovery or development of new medicines.
Entries will be judged on the answers to a number of key questions:
The Award is open to any person, group or company that has achieved a genuinely ground-breaking advance during the qualifying period of 1 June 2022 - 30 June 2023. We welcome entries that are active in the life sciences ecosystem – from early-stage research through to clinical proof-of-concept developments. Achievements we wish to recognise include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.
This new Scrip Award seeks to recognise early clinical advances in oncology made by small biopharma companies. The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.
This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.
To enter this category, please answer the following:
Please note, Preclinical advances may work best in MSD’s Innovation Award and later-stage studies and those by big pharma firms may be best suited to the Clinical Advance of the Year category.
Entries should be from clinical-stage firms with novel products that have shown proof-of-concept in some way between 1 June 2022 - 30 June 2023, such as a clinical study that has been reported by the firm, presented for peer review at a medical meeting or published in a scientific journal. Entrants must have played a role in the clinical study and all joint parties must be disclosed in the application.
The Pharma Company of the Year Award honours outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 June 2022 - 30 June 2023.
This special Award is chosen by Scrip’s senior editorial team, based on a variety of key metrics:
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.
For this special Award, candidates must be nominated by a third party. The nomination should outline in no more than 750 words what the nominee has accomplished during his/her career and say why they are worthy of this Award.
All nominations must include:
Nominees may be retired or semi-retired but will still be active in the industry in some capacity. For this special Award, candidates must be nominated by a third party.
Vaidheesh Annaswamy
Laura Brown
Dr Ajit Dangi
Laurie Halloran
Brian Hargreaves
Trevor Jones
Viren Mehta
Mads Øvlisen
Phornvit Phacharintanakul
Peter Pitts
Andy Smith
Robert Spiegel
Brian Tempest
Strong business leadership track record of over 35 years in Health care and FMCG industries in multi countries focusing on sustainable and responsible growth in J&J and GSK.
Currently CEO North Star Asia LLP, Management Consultant and Senior Advisor, PAG Holdings Hong Kong. Mr. Vaidheesh was also previously MD and VP (South Asia), GSK.
Created new business models and markets, turned around declining businesses, flourished in various leadership situations. Winner of Economics Times award as the “Most Promising Asian Leader of the year -2016”. Won the prestigious Michel Porter award for “Shared value-2016”. President of OPPI 2017-2020. Winner of the prestigious Fair business practices Trophy. Signed and executed MOU with China Communist Party School for health care initiatives for J&J. Honorary Fellow of the Minimal Access Surgeons Association of India.
Dr Laura Brown is Course Director of the MSc in Clinical Research, University of Cardiff and a Training and QA Consultant.
Dr Brown has held a number of international and senior management positions in the pharmaceutical industry. She has worked for several international companies including GlaxoWellcome, Hoechst Marion Roussel and Phoenix International.
She was a member of the Editorial board of the Good Clinical Practice Journal for 10 years. She is author of several books including Project Management for the Pharmaceutical Industry, a Practical Guide to the Clinical Trial Directive and several articles on the new EU Clinical Trial Regulation.
Dr. Ajit Dangi is President & CEO of Danssen Consulting, a strategy firm specialising in Life Sciences and Healthcare. He has served as the Chairman of the Board of Fulford India Ltd., a subsidiary of Merck & Co. Inc. USA for ten years. He is also Director of Atul Bioscience Ltd. India. Dr. Dangi has served as President & Executive Director of Johnson & Johnson India Ltd . where he worked for twenty years in various capacities. He has also served as Director General of Organisation of Pharmaceutical Producers of India (OPPI) for over seven years.
Dr. Dangi is a Graduate in Chemistry from University of Bombay and later earned his Masters and Doctorate ( Ph.D. ) degrees in Pharmaceutical Chemistry from University of London , England . He has also undergone Advanced Management Program from Kellogg Graduate School of Business, Chicago, USA.
Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do.
Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals.
Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington University and Harvard University. Laurie earned a Bachelor of Science in Nursing from Russell Sage College and a Master of Science in Management from Lesley University. She is also a Prosci Certified Change Practitioner.
Jones is chairman of the Oxford-based AI drug discovery company e-Therapeutics and a member of the board of the USA vaccine company Techimmune LLC. He was formerly R&D Director of the Wellcome Foundation, a director of Allergan Inc. and Director General of the Association of the British pharmaceutical industry (ABPI ). He is a visiting professor at Kings College London
Viren founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced biopharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years.
Gather Health has been one of Viren’s recent initiatives to empower patients while enhancing physician productivity. Gather Health aims to bring together patient’s providers and patient’s personal network, enabling patient to get real-time and active resources and motivation from this team to improve outcomes.
Viren's biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. His philanthropic work in ecology and education through viram Foundation includes board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA).
Viren began his career at Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve global growth while enhancing access to healthcare innovations.
Until 2000, Mads Øvlisen was President and CEO of Novo Nordisk A/S, Denmark, and served as its chair until 2006. His board positions included the chairmanship of LEGO A/S, Bang & Olufsen A/S, the Royal Danish Theatre, the Danish Arts Council, the Danish Council on Corporate Social Responsibility, and the Danish Mediation and Complaints-Handling Institution for Responsible Business Conduct (the Danish OECD national contact point).
He was a member of the board of United Nations Global Compact, chaired the Compact’s advisory group on supply chain sustainability and was a professor of corporate social responsibility at the Copenhagen Business School.
Peter Pitts is a Visiting Professor at the University of Paris Medical School and President of the Center for Medicine in the Public Interest. He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Pitts is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. (CIOMS is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949.) He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. Pitts lives in New York City.
Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, real world evidence, social media, off label-communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.
Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and Glaxo, and after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in Anti-Infectives Strategic Product Development (SPD). In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for four life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.
After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.
In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advised big pharma and smaller life science companies on the valuation and commercialisation of their products and returned to the City at the end of 2017 to work at Edison.
Dr Brian Tempest has held many Non-Executive roles in the Corporate, Educational and NGO Sectors. These positions include Pharmaceuticals, Hospital Management, Medical Diagnostics, Packaging, Financial Services, University Advisory Boards and the United Nations Patent Pool. He is currently Non-Executive Chairman of Touch Medical Media Group Holdings in the UK and is on the Board of a number of international Healthcare Companies as well as advising others from Europe and Asia.
Brian has previously worked for GSK, Pfizer, Sanofi and Sun Pharmaceuticals in leadership positions. He holds FRSC, FRSM, BSc, PhD and DSc qualifications and now resides in Wales, UK.
Ready to submit your entry to the Scrip Awards 2023? Enter today to be in with a chance of winning a prestigious Scrip Award
Enter Now
Sponsorship provides a wealth of opportunities, from thought leadership, to brand awareness and lead generation. Find out more about the numerous sponsorship opportunities available.
Sponsor Opportunities
Looking to attend the Scrip Awards 2023? Book your table for the awards!
BOOK YOUR TABLE
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
Dalriada Drug Discovery is a fully-integrated small molecule drug discovery CRO located in Toronto, Canada, supporting global biotech and pharma innovators through its TURN-KEY™ model, where R&D is perfectly aligned with business support and IP management. Dalriada’s team has been fully integrated from day one and is high on experience and capability. The product of this can be seen in our strong performance & track record, and in our roster of happy clients.
This year Dalriada turns six. That’s six years of driving innovative small-molecule programs from concept to IND. Over that time, our insightful team and our capabilities have significantly grown, and we now offer global clients a wide breadth of top-notch drug discovery services that includes medicinal and computational chemistry, ADME, biological sciences, proteomics, structural biology, preclinical development, and other disciplines.
We are disease-area agnostic but hold deep experience across multiple disease areas. We additionally have major technical strengths in areas such as covalent inhibition and protein degradation.
In today’s drug discovery marketplace we provide unique value and commercial offering. We invite potential clients to visit our newly enhanced website, www.dalriadatx.com, and to connect with us for exploratory conversations.
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.
As a leading global clinical research organization, Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. Our employees have a deep conviction in what we do, and together with our customers, we are shaping the next generation of therapies, one patient at a time. What we do, we do With Heart™.
Quris-AI is an artificial intelligence innovator that is disrupting the drug development process. Quris' Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. We are led by a team of top scientists and strategic investors and are actively preparing for clinical testing with our first AI-based drug.
As a global company with operations across Asia, Europe, and North America, WuXiAppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXiAppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXiAppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
The Scrip Awards are now in the 19th year of connecting hundreds of pioneers in global healthcare. Take a look back at our previous Awards and winners.
